Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of ocular disease

a technology for ocular diseases and ascomycin, which is applied in the field of rapamycin and ascomycin for the treatment of ocular diseases, can solve the problems of difficult diagnosis and treatment, corresponding increase of tear osmolarity, and -gritty eye feeling, so as to reduce the time of onset, prevent, and lessen the severity

Inactive Publication Date: 2005-02-03
PEYMAN GHOLAM A DR
View PDF40 Cites 71 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The method may prevent, decrease the time of onset, or lessen the severity of a wide variety of ocular conditions such as retinitis pigmentosa, ocular irritation following corneal surgery (e.g., LASIK surgery), age related macular degeneration, diabetic retinopathy, dry eye disease, scleritis, papillitis, and uveitis, as examples. Rapamycin may be administered in combination with Cyclosporin A and / or tacrolimus for intraocular administration without toxicity-limiting effects. Rapamycin may also be administered in combination with antibiotics without toxicity-limiting effects.

Problems solved by technology

It is a common complaint, affecting three million people in the United States alone, yet it is difficult to diagnose and treat.
The loss of water from the tear film causes a corresponding rise in tear osmolarity.
The increased osmolarity results in symptoms such as a sandy-gritty feeling in the eye, burning, irritation, or a foreign-body sensation that worsens during the day.
Surgery has its attendant risks, and may not be a viable option in older patients.
In addition, tacrolimus is well tolerated locally and only occasionally causes mild irritation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] Methods are disclosed to ameliorate ocular conditions in need of treatment by intraocularly administering compositions containing rapamycin, ascomycin, and / or combinations of rapamycin and ascomycin as an active component. Intraocular administration provides direct effects to the eye while avoiding problems associated with systemic administration. Rapamycin is also known as sirolimus, RAPA and Rapamune. It is a triene macrolide antibiotic derived from Streptomyces hydroscopicus and originally developed as an antifungal agent. Subsequently, it has shown anti-inflammatory, anti-tumor, and immunosuppressive properties. Ascomycin is also known as pimecrolimus, Immunomycin, and FR-900520. It is an ethyl analog of tacrolimus (FK506) and has strong immunosuppressant properties. It inhibits Th1 and Th2 cytokines, and preferentially inhibits activation of mast cells, and is used to treat contact dermatitis and other dermatological conditions. Rapamycin and ascomycin are commercially a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and / or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg / ml drug to about 50 μg / ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg / mi to about 200 μg / ml may be used. Rapamycin and / or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

Description

FIELD OF THE INVENTION [0001] The invention is directed to the use of rapamycin and ascomycin for therapeutic treatment of ocular conditions, including dry eye disease. BACKGROUND [0002] Dry eye disease encompasses any condition where the tear film loses water and becomes more concentrated. It is a common complaint, affecting three million people in the United States alone, yet it is difficult to diagnose and treat. The loss of water from the tear film causes a corresponding rise in tear osmolarity. The increased osmolarity results in symptoms such as a sandy-gritty feeling in the eye, burning, irritation, or a foreign-body sensation that worsens during the day. Patients suffering from dry eye disease complain of mild to severe symptoms, with signs ranging from minimal superficial punctate keratitis to corneal perforation. [0003] Dry eye disease has a chronic remitting and relapsing nature and may result from a number of factors. The disease may be a natural part of the aging proces...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61K9/22A61K31/33A61K31/4745A61P27/02A61P37/06A61P37/08
CPCA61K9/0051A61K31/4745A61K31/33A61P19/02A61P19/08A61P27/02A61P27/12A61P29/00A61P33/02A61P37/06A61P37/08A61P9/10
Inventor PEYMAN, GHOLAM
Owner PEYMAN GHOLAM A DR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products